anti csf1r  (Bio X Cell)

Journal: bioRxiv

Article Title: Myeloid CD209 impairs T-cell activation by inducing ICAM-2–ERM–dependent cortical stiffening

doi: 10.64898/2026.01.19.699861

Figure Lengend Snippet: a-e. Flow cytometry analysis the proportions of CD4 + T and CD8 + T cells of MC38 (n=13/12), B16 (n=13/13), ID8 (n=11/12) and LLC (n=13/13) tumor microenvironments following control mAb or anti-hCD209 mAb treatment. f-i. Flow cytometry analysis of the proportions of CD4 + IFN-γ + T cells and CD8 + IFN-γ + T cells in the MC38, B16, ID8 and LLC tumor microenvironments following control mAb or anti-hCD209 mAb treatment. j-l. The expression levels of IFN-γ in the tumor culture supernatant and mouse serum of MC38, LLC, B16 and ID8 tumor-bearing mice after control mAb or anti-hCD209 mAb treatment were detected via ELISA. m. MC38 tumors were subcutaneously implanted into hCD209-KI mice, followed by anti-control, anti-hCD209 mAb, anti-control+αCD8 or anti-hCD209+αCD8 treatment (n=12/12/12/12), and tumor growth is shown ( m ). The depletion of CD8+ T cells is shown ( n ). o-q. Tumors were implanted as described in m , followed by treatment with anti-control, anti-hCD209 mAb, anti-control+αCSF1R or anti-hCD209+αCSF1R (n=12/12/12/12), and tumor growth is shown ( o ). The depletion of CSF1R + cells is shown ( p-q ). *: P<0.05; **: P<0.01; ***: P<0.005; ****: P<0.001 based on two-tailed unpaired t tests ( b-l, n, p and q ); Two-way ANOVA ( m and o ); All error bars represent the S.E.M. of technical replicates. Data are representative of two independent experiments ( a-q ).

Article Snippet: The human IgG4 isotype control (clone R1, (Selleck Cat# A2052, RRID: AB_3713065)), anti-mouse PD-1 (clone RMP1-14, (Selleck Cat# A2122, RRID:AB_3644244)), anti-mouse CD8a (clone 2.43, (Selleck Cat# A2102, RRID:AB_3099521)), and anti-mouse CSF1R (clone AFS98, (Bio X Cell Cat# BE0213, RRID:AB_2687699)).

Techniques: Flow Cytometry, Control, Expressing, Enzyme-linked Immunosorbent Assay, Two Tailed Test

Journal: bioRxiv

Article Title: Donor Macrophage Depletion Permits Post-Transplant Tolerance Induction in a Murine Islet Transplant Model

doi: 10.64898/2026.01.08.698403

Figure Lengend Snippet: (A) Diagram of treatment schedule for delayed tolerance protocol. BALB/c donors are treated with two doses of 500 μg anti-CD115 antibody intraperitoneally (i.p.) as described in Methods. Donor macrophage-depleted (DMac-Depleted) or non-depleted (Control) islets are transplanted on day 0 into diabetic C57BL/6 mice. Recipients are then treated with two doses of donor ECDI-SPs on POD+1 and POD+7. (B) Representative FACS plots depicting gating strategy to count pancreatic islet macrophages. BALB/c donors received two doses of 500 μg intraperitoneal anti-CD115 antibody on days-11 and -7 prior to islet isolation on day0. Islets were harvested and immediately dissociated before staining for flow cytometry. Two donors were pooled for each data point, and the number of macrophages was normalized to the number of donors. The bar graph depicts the average number of donor islet macrophages (DMac) per donor, N=4 for each group. (C) Blood glucose was tracked to determine graft function, with two consecutive days of blood glucose >250 mg/dL defined as graft rejection. Survival of grafts with each treatment regimen is represented in the survival plot as days post-transplant, significance *p < 0.05. ***p < .005.

Article Snippet: Donor BALB/c mice were treated with anti-CD115 (anti-CSF1R, BioXCell #BE0213) antibody to deplete pancreatic islet resident macrophages.

Techniques: Control, Isolation, Staining, Flow Cytometry